Ken Colley, MD, PhD

Dr. Colley is a physician-scientist with more than 20 years of experience focused on developing small and large molecule therapeutic products from R&D through human proof-of-concept mid-stage clinical studies. As Executive Medical Director, Medical Monitor, and Head of Product Development for emerging biotech and large biopharma companies, he has overseen development programs across clinical pharmacology and translational medicine, first-in-human, Phase 1, and human proof of concept Phase 2+ studies. In addition to completing numerous successful Phase 1 and Phase 2 studies, Dr. Colley’s experience also extends into later stage medical safety analyses, submission dossiers, market approval, and medical affairs.

Dr. Colley holds an MD and PhD in Molecular Pharmacology from Georgetown University and a Bachelor’s in Biological Sciences from Stanford University.